Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 695 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with... November 6, 2024 News digest – targeted radiation beam, precision medicine and our early... October 17, 2020 Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated... January 28, 2022 A 27-Year-Old Woman Passed Away. The Note She Wrote The Day... June 19, 2019 Load more HOT NEWS Is there a right way to check your body for cancer? Precision drug slows progression of advanced breast cancer Cancer Prevention Message Is Key for HPV Vaccination Discussions with Parents Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer
